Typhoid Fever - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 43 pages report, published by Global Markets Direct

Keywords : Typhoid Fever Therapeutic Products under Development, Key Players in Typhoid Fever Therapeutics, Typhoid Fever Pipeline Overview, Typhoid Fever Pipeline, Typhoid Fever Pipeline Assessment

Report ThumbnailSeptember-2013
Typhoid Fever - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Typhoid Fever - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. Typhoid Fever - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Typhoid Fever.
- A review of the Typhoid Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Typhoid Fever pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Typhoid Fever.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Typhoid Fever, H2 2013 7
  • Products under Development for Typhoid Fever - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Typhoid Fever, H2 2013 7
  • Products under Development for Typhoid Fever - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Nanotherapeutics, Inc., H2 2013 16
  • Novartis AG, H2 2013 17
  • Bharat Biotech International Limited, H2 2013 18
  • Shantha Biotechnics Limited, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Typhoid Fever Therapeutics - Drug Profile Updates 36
  • Typhoid Fever Therapeutics - Dormant Products 38
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Typhoid Fever Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Typhoid Fever 7
  • Typhoid Fever Therapeutics under Development by Companies 9
  • Typhoid Fever Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Typhoid Fever Therapeutics - Products under Development by Companies 14
  • Typhoid Fever Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Typhoid Fever Therapeutics Development 16
  • Nanotherapeutics, Inc. 16
  • Novartis AG 17
  • Bharat Biotech International Limited 18
  • Shantha Biotechnics Limited 19
  • Typhoid Fever - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • GelVac - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • M-10ZH09 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Typhoid TT Vaccine - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Vi-CRM197 PCMV - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Vi-Diptheria Toxoid Conjugate Typhoid Vaccine - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Bivalent Enteric Fever Conjugate Vaccine - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Vi-PspA Vaccine - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • OmpC-Vi Conjugate Vaccine - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Typhetec - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Typhoid Fever Therapeutics - Drug Profile Updates 36
  • Typhoid Fever Therapeutics - Dormant Products 38
  • Typhoid Fever - Product Development Milestones 39
  • Featured News & Press Releases 39
  • Aug 26, 2013: Bharat Biotech Launches Typbar-TCV for long-term protection 39
  • Mar 11, 2013: Prokarium And University Of Birmingham Receive £0.4m Grant To Develop Next Generation Vaccines 39
  • Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate 40
  • Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine 40
  • Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine 41
  • Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study 41
  • Oct 30, 2002: Bayer Corporation Submits Additional New Drug Application For Once-Daily Cipro XR. 41
  • Appendix 42
  • Methodology 42
  • Coverage 42
  • Secondary Research 42
  • Primary Research 42
  • Expert Panel Validation 42
  • Contact Us 43
  • Disclaimer 43

Please select a license type

Share

Related Products

Global Markets DirectTyphoid Fever - Pipeline Review, H2 2013Product ThumbnailTyphoid Fever - Pipeline Review, H2 2013, Industry ReportProduct #: 113312
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved